J Transcat Intervent.2022;30:eA202209.
Comments about REVIVED-BCIS2 Trial
Fernando Mendes Sant’Anna
, Lucas Bonacossa Sant’Anna
DOI: 10.31160/JOTCI202230A202209
FINAL CONSIDERATIONS
This clinical trial supports the increasingly growing importance of using drug therapy oriented by the most updated guidelines to treat ischemic ventricular dysfunction, regardless of patients being revascularized or not. This had already been demonstrated in the ISCHEMIA trial and, mainly in analysis of subgroups of this study, which enrolled 398 patients with ejection fraction between 35% and 45%, there was a clear benefit of revascularization over OMT after a 4-year follow-up.
Other considerations can only be inferred after a long-term follow-up of these patients, which will allow better evaluation of the impact of revascularization in clinical outcomes. Further studies are warranted, mainly with a more precise approach of the anatomical and functional assessment of coronary lesions and their correlation with ischemia and ventricular dysfunction.
[…]
194